Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nanjing Univ. of Chinese Medicine NLRP3 compound E1
- Development stage
- Unknown
- Lead developer
- Nanjing University of Chinese Medicine
01
Overview
Nanjing Univ. of Chinese Medicine NLRP3 compound E1: sourced facts only. name: "Thus, E1 has been considered a novel and potent NLRP3 inhibitor." [PMID:41072014]; target: "Thus, E1 has been considered a novel and potent NLRP3 inhibitor." [PMID:41072014]; developer: "Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, P. R. China." [PMID:41072014]
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on Nanjing Univ. of Chinese Medicine NLRP3 compound E1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Univ. of Chinese Medicine NLRP3 compound E1.